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1. INTRODUCTION {#cas13457-sec-0001}
===============

Every year approximately 215 000 children (aged 0‐14 years) are diagnosed with cancer globally, while 80 000 children die from the disease.[1](#cas13457-bib-0001){ref-type="ref"} Epidemiological analyses of differences in incidence and survival between countries and over time are important to understand etiological factors and to monitor changes in disease burden and progress in the treatment of childhood cancers.

The incidence of childhood cancer overall and by diagnostic subgroup has been reported in the International Incidence of Childhood Cancer (IICC) for many countries, including Japan and England.[2](#cas13457-bib-0002){ref-type="ref"}, [3](#cas13457-bib-0003){ref-type="ref"} In Europe, survival analysis has been performed to evaluate the quality of care for children with cancer in each country or region in several studies, including the Automated Childhood Cancer Information System (ACCIS)[4](#cas13457-bib-0004){ref-type="ref"} and EUROCARE‐5.[5](#cas13457-bib-0005){ref-type="ref"} In 2012, the global surveillance of cancer survival program (the CONCORD‐2 study),[6](#cas13457-bib-0006){ref-type="ref"}, [7](#cas13457-bib-0007){ref-type="ref"} which includes childhood leukemia, was initiated using population‐based cancer registry data from 67 countries. In Japan, population‐based studies for childhood cancer comparisons to other countries are scarce, although some recent studies show childhood cancer incidence[8](#cas13457-bib-0008){ref-type="ref"}, [9](#cas13457-bib-0009){ref-type="ref"} or survival,[10](#cas13457-bib-0010){ref-type="ref"} and several cancer registries contributed to the IICC and CONCORD‐2 studies.[2](#cas13457-bib-0002){ref-type="ref"}, [7](#cas13457-bib-0007){ref-type="ref"} In England, population‐based incidence and survival for childhood cancer have been reported since 1980s.[11](#cas13457-bib-0011){ref-type="ref"}, [12](#cas13457-bib-0012){ref-type="ref"}, [13](#cas13457-bib-0013){ref-type="ref"} In the current study, we compared incidence and time trends in survival for childhood cancer between Japan and England during the period 1993‐2010, to gain insight into the progress against childhood cancer in both countries.

2. METHODS {#cas13457-sec-0002}
==========

2.1. Data {#cas13457-sec-0003}
---------

This study was based on data from population‐based cancer registries in Japan and England. It included all children (0‐14 years) diagnosed with cancer between 1993 and 2010 residing in 6 Japanese prefectures (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki)[10](#cas13457-bib-0010){ref-type="ref"} or in England. Japanese data were obtained from the Monitoring of Cancer Incidence in Japan (MCIJ) project and the Japanese Cancer Survival Information for Society (J‐CANSIS) project,[10](#cas13457-bib-0010){ref-type="ref"} while data for England were obtained from the Office for National Statistics. A standard set of variables included basic demographic data (age, sex and country), information on the tumor (date of diagnosis, site and morphology) and on follow‐up (date of last contact and vital status). Follow‐up information was available at least 5 years after diagnosis in Japan although the patient follow‐up system differs for each cancer registry.[10](#cas13457-bib-0010){ref-type="ref"} Within the Japanese data, vital status information was available for patients diagnosed during 1993‐2008. In the English data, the vital status was last updated on 31 December 2015.

We included only records of malignant cancers (behavior code/3) defined in the International Classification of Disease for Oncology, 3rd edition (ICD‐O‐3).[14](#cas13457-bib-0014){ref-type="ref"} Non‐malignant or borderline central nervous system tumors such as craniopharyngioma, meningioma, ganglioglioma, benign teratoma and pilocytic astrocytoma were all excluded. Skin carcinomas were also excluded. Cancers were grouped into 12 main diagnostic categories according to the International Classification of Childhood Cancer, 3rd edition (ICCC‐3).[15](#cas13457-bib-0015){ref-type="ref"} We modified some subgroups of ICCC‐3, based on the topography and morphology codes from ICD‐O‐3 (Table [S1](#cas13457-sup-0001){ref-type="supplementary-material"}).

These data partially overlapped with the data used in the IICC or CONCORD‐2, although for participating registries or study periods, inclusion criteria were not completely matched. There were few discrepancies in the incidence of each cancer between both datasets, with the exception of central nervous system (CNS) tumors and all cancers combined.

2.2. Statistical analysis {#cas13457-sec-0004}
-------------------------

Incidence rates were calculated as the average annual number of children newly diagnosed with cancer per million children. Age‐standardized incidence rates (ASR) were calculated by the direct method, using the weights of the world standard population for the age groups under 15 years (0, 1‐4, 5‐9 and 10‐14 years).[16](#cas13457-bib-0016){ref-type="ref"}, [17](#cas13457-bib-0017){ref-type="ref"} Changes in incidence rates over time were calculated using a Poisson regression model, divided into 3 time periods (1993‐1998, 1999‐2004 and 2005‐2010) and adjusted for age‐group, and expressed as average annual percent change (AAPC). Differences in incidence rates between the 2 countries were measured with Poisson regression models and expressed as the incidence rate ratio (IRR), using English data as the reference. These ratios were adjusted for time period and age group. Observed population‐based survival was estimated by cancer type in each time period (1993‐1996, 1997‐2000, 2001‐2004 and 2005‐2008), using the Kaplan--Meier method. We used the classic cohort approach to calculate 1‐year and 5‐year survival for children diagnosed during 1993‐2008, and 10‐year survival for children diagnosed during 1993‐2000 in Japan and during 1993‐2004 in England. We used the period approach to predict 10‐year survival for children diagnosed during 2001‐2008 in Japan and during 2005‐2008 in England, as this approach allows for the prediction of survival where 10‐year follow‐up is not yet available.[18](#cas13457-bib-0018){ref-type="ref"} The analysis was carried out using Stata 14. This study was approved by the London‐South East Research Ethics Committee (07/MRE01/52) and the Research Ethics Committee of the Osaka International Cancer Institute (No. 1707105096).

3. RESULTS {#cas13457-sec-0005}
==========

3.1. Data quality {#cas13457-sec-0006}
-----------------

Analyses were based on 5192 cases in Japan and 21 295 cases in England between 1993 and 2010. Table [1](#cas13457-tbl-0001){ref-type="table"} shows the quality criteria for validity and completeness of the data over time in each country. The proportion of records from death certificate only (DCO) in Japan reduced from 3.1% in 1993‐1998 to 0.9% in 2005‐2010, whereas that in England has been stable at under 1% since 1993. The proportion of unspecified histology (not otherwise specified \[NOS\], ICD‐O‐3 morphology code 8000 to 8004) also decreased from 4.3 to 2.1% in Japan, whereas that in England was around 2% from 1993 to 2010.[19](#cas13457-bib-0019){ref-type="ref"} The proportion of multiple primary cancers was under 1% in both countries, except in the Japanese data for 2005‐2010. We included NOS for both incidence and survival analysis while DCO and multiple primary cancers were excluded in survival analysis.

###### 

Indicators of data quality of population‐based cancer registries between Japan and England

                                Records   Unspecified histology[a](#cas13457-note-0003){ref-type="fn"}   DCO[b](#cas13457-note-0004){ref-type="fn"}   Multiple primary cancers[b](#cas13457-note-0004){ref-type="fn"}              
  ----------------------------- --------- -------------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------- ----- ---- -----
  Japan (6 cancer registries)                                                                                                                                                                                                      
  1993‐1998                     1947      84                                                             4.3                                          60                                                                3.1   15   0.8
  1999‐2004                     1704      74                                                             4.3                                          21                                                                1.2   15   0.9
  2005‐2010                     1541      32                                                             2.1                                          14                                                                0.9   33   2.1
  England                                                                                                                                                                                                                          
  1993‐1998                     7019      152                                                            2.2                                          38                                                                0.5   35   0.5
  1999‐2004                     7087      101                                                            1.4                                          14                                                                0.2   49   0.7
  2005‐2010                     7189      169                                                            2.4                                          14                                                                0.2   50   0.7

DCO, records registered from death certificate only.

ICD‐O‐3 morphology code 8000 to 8004.

We included for incidence analysis, but excluded for survival analysis.
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3.2. Trends in incidence of childhood cancer in Japan and England {#cas13457-sec-0007}
-----------------------------------------------------------------

Table [2](#cas13457-tbl-0002){ref-type="table"} shows trends in incidence for each cancer type in both countries. Overall, the age‐standardized incidence rate (ASR) of all childhood cancers combined seemed to decrease in Japan (ASR 1993‐1998: 127 per million vs 2005‐2010: 116 per million; see Table [2](#cas13457-tbl-0002){ref-type="table"} and Figure [S1](#cas13457-sup-0001){ref-type="supplementary-material"}A). However, incidence for all cancers except neuroblastoma was stable (AAPC = 0.2%, \[95% CI −0.4‐0.8\], Table [2](#cas13457-tbl-0002){ref-type="table"}). A steep decline was observed in neuroblastoma (NBL) in infants (age \<1 year) in Japan (average age‐specific incidence rate changed from 191 to 27 per million; Table [2](#cas13457-tbl-0002){ref-type="table"}, Figure [S1](#cas13457-sup-0001){ref-type="supplementary-material"}B). In England, the incidence of all childhood cancers increased from 1993‐1998 to 1999‐2004, and plateaued (ASR 1993‐1998:129, 1999‐2004: 133, 2005‐2010:134). Incidence increased significantly during 1993‐2010 in England for malignant bone tumors (AAPC = 1.3%, \[95% CI 0.1‐2.5\]) and germ cell tumors (GCT; AAPC = 1.6%, \[0.1‐3.1\]), but not for the other cancer types.

###### 

Trends in incidence of childhood cancer (age 0‐14 y) by period of diagnosis and cancer type in Japan and England

                                 1993‐1998   1999‐2004                                      2005‐2010         Time trend                                                                                                                                                  
  ------------------------------ ----------- ---------------------------------------------- ----------------- ------------ ---------------------------------------------- ----------------- ------ --------------------------------------------- ----------------- ------ --------------
  Japan                                                                                                                                                                                                                                                                   
  I. Leukemias                   670         43.2                                           \[39.9‐46.6\]     558          39.6                                           \[36.3‐43\]       566    43.0                                          \[39.4‐46.6\]     0.1    \[−1.1‐0.8\]
  II\. Lymphomas                 197         12.3                                           \[10.5‐14\]       158          10.4                                           \[8.8‐12\]        154    10.7                                          \[9‐12.4\]        −0.7   \[−2.5‐1.1\]
  III\. CNS tumors               290         18.3                                           \[16.1‐20.4\]     257          17.5                                           \[15.4‐19.7\]     249    18.3                                          \[16‐20.6\]       0.1    \[−1.3‐1.5\]
  IV\. Neuroblastoma             282         21.2                                           \[18.7‐23.7\]     219          17.4                                           \[15.1‐19.7\]     103    9.0                                           \[7.2‐10.7\]      −6.4   \[−8.1‐4.7\]
  NBL infants (age \< 1 y)       192         191.3[a](#cas13457-note-0006){ref-type="fn"}                     121          128.4[a](#cas13457-note-0006){ref-type="fn"}                     23     27.3[a](#cas13457-note-0006){ref-type="fn"}                     n.a.   
  NBL children aged 1‐14 y       90          6.9[b](#cas13457-note-0007){ref-type="fn"}     \[5.5‐8.4\]       98           8.1[b](#cas13457-note-0007){ref-type="fn"}     \[6.5‐9.7\]       80     7.4[b](#cas13457-note-0007){ref-type="fn"}    \[5.8‐9\]         1.3    \[−2.2‐2.7\]
  V. Retinoblastoma              56          4.3                                            \[3.1‐5.4\]       57           4.6                                            \[3.4‐5.7\]       57     5.1                                           \[3.8‐6.5\]       1.5    \[−1.6‐4.5\]
  VI\. Renal tumors              52          3.8                                            \[2.7‐4.8\]       47           3.5                                            \[2.5‐4.5\]       36     3.1                                           \[2.1‐4.1\]       −1.7   \[−5.2‐1.8\]
  VII\. Hepatic tumors           36          2.6                                            \[1.7‐3.4\]       40           3.1                                            \[2.1‐4.1\]       37     3.2                                           \[2.2‐4.2\]       1.6    \[−2.2‐5.3\]
  VIII\. Malignant Bone tumors   83          4.4                                            \[3.4‐5.3\]       83           4.9                                            \[3.9‐6\]         67     4.3                                           \[3.3‐5.3\]       −0.1   \[−2.7‐2.5\]
  IX\. Soft tissue sarcomas      96          5.9                                            \[4.7‐7.1\]       104          7.2                                            \[5.8‐8.6\]       95     6.8                                           \[5.4‐8.2\]       1.3    \[−1‐3.7\]
  X. Germ cell tumors            128         7.6                                            \[6.2‐8.9\]       113          7.4                                            \[6‐8.7\]         118    8.5                                           \[6.9‐10\]        0.8    \[−1.3‐2.9\]
  XI\. Other carcinomas          42          2.2                                            \[1.5‐2.9\]       47           2.8                                            \[2‐3.6\]         43     2.8                                           \[1.9‐3.6\]       1.8    \[−1.6‐5.3\]
  XII\. Unspecified cancers      15          1.0                                            \[0.5‐1.5\]       21           1.5                                            \[0.8‐2.1\]       16     1.2                                           \[0.6‐1.8\]       1.9    \[−3.7‐7.4\]
  Total                          1947        126.6                                          \[120.9‐132.3\]   1704         119.9                                          \[114.1‐125.6\]   1541   115.9                                         \[110‐121.8\]     −0.6   \[−1.1‐0\]
  Total (excluding NBL)          1665        105.4                                          \[100.2‐110.5\]   1485         102.5                                          \[97.2‐107.8\]    1438   107.0                                         \[101.3‐112.6\]   0.2    \[−0.4‐0.8\]
  England                                                                                                                                                                                                                                                                 
  I. Leukemias                   2462        45.8                                           \[43.9‐47.6\]     2493         48.0                                           \[46.1‐49.9\]     2436   46.6                                          \[44.7‐48.4\]     0.1    \[−0.3‐0.5\]
  II\. Lymphomas                 802         13.7                                           \[12.8‐14.7\]     815          13.7                                           \[12.8‐14.7\]     864    14.7                                          \[13.7‐15.7\]     0.7    \[−0.1‐1.5\]
  III\. CNS tumors               1252        22.6                                           \[21.4‐23.9\]     1241         22.9                                           \[21.6‐24.2\]     1226   22.8                                          \[21.5‐24.1\]     0.0    \[−0.6‐0.7\]
  IV\. Neuroblastoma             476         9.4                                            \[8.6‐10.3\]      468          10.0                                           \[9.1‐10.9\]      461    9.3                                           \[8.4‐10.1\]      −0.2   \[−1.2‐0.9\]
  NBL infants (age \<1 y)        128         34.7[a](#cas13457-note-0006){ref-type="fn"}                      157          45.4[a](#cas13457-note-0006){ref-type="fn"}                      149    38.5[a](#cas13457-note-0006){ref-type="fn"}                     n.a.   
  NBL children aged 1‐14 y       348         7.30[b](#cas13457-note-0007){ref-type="fn"}    \[6.5‐8.1\]       311          7.0[b](#cas13457-note-0007){ref-type="fn"}     \[6.2‐7.8\]       312    6.8[b](#cas13457-note-0007){ref-type="fn"}    \[6.1‐7.6\]       −0.6   \[−1.9‐0.7\]
  V. Retinoblastoma              225         4.6                                            \[4‐5.2\]         203          4.4                                            \[3.8‐5.1\]       219    4.5                                           \[3.9‐5.1\]       −0.2   \[−1.8‐1.3\]
  VI\. Renal tumors              434         8.5                                            \[7.7‐9.3\]       449          9.3                                            \[8.5‐10.2\]      449    9.0                                           \[8.2‐9.9\]       0.5    \[−0.6‐1.6\]
  VII\. Hepatic tumors           74          1.5                                            \[1.1‐1.8\]       93           1.9                                            \[1.5‐2.3\]       89     1.8                                           \[1.4‐2.1\]       1.5    \[−1‐3.9\]
  VIII\. Malignant bone tumors   318         5.2                                            \[4.7‐5.8\]       355          5.7                                            \[5.1‐6.3\]       371    6.1                                           \[5.5‐6.7\]       1.3    \[0.1‐2.5\]
  IX\. Soft tissue sarcomas      486         8.9                                            \[8.1‐9.6\]       470          8.6                                            \[7.8‐9.4\]       493    9.0                                           \[8.2‐9.8\]       0.2    \[−0.8‐1.3\]
  X. Germ cell tumors            221         4.0                                            \[3.5‐4.5\]       233          4.2                                            \[3.6‐4.7\]       270    4.8                                           \[4.2‐5.4\]       1.6    \[0.1‐3.1\]
  XI\. Other carcinomas          201         3.4                                            \[2.9‐3.8\]       215          3.5                                            \[3‐4\]           230    3.8                                           \[3.3‐4.3\]       1.0    \[−0.5‐2.6\]
  XII\. Unspecified cancers      68          1.2                                            \[1‐1.5\]         52           1.0                                            \[0.7‐1.3\]       81     1.5                                           \[1.2‐1.8\]       1.7    \[−1.1‐4.5\]
  Total                          7019        128.8                                          \[125.7‐131.8\]   7087         133.3                                          \[130.2‐136.5\]   7189   133.8                                         \[130.7‐136.9\]   0.3    \[0.1‐0.6\]
  Total (excluding NBL)          6543        119.4                                          \[116.4‐122.3\]   6619         123.3                                          \[120.3‐126.3\]   6728   124.5                                         \[121.5‐127.5\]   0.4    \[0.1‐0.7\]

AAPC, average annual percentage of change; ASR, age‐standardized incidence rate (person per million‐years); CNS, central nervous system; NBL, neuroblastoma; n.a., AAPCs of "NBL infants (age \< 1 y)" were not calculated because models were not fitted.

Age‐specific incidence rate.

Using records, population and world standard population in age 1‐4, 5‐9, 10‐14 y.

John Wiley & Sons, Ltd

3.3. Comparison of incidence of each cancer type between countries {#cas13457-sec-0008}
------------------------------------------------------------------

Table [3](#cas13457-tbl-0003){ref-type="table"} and Figure [1](#cas13457-fig-0001){ref-type="fig"} show ASR in the total period of 1993‐2010 and the incidence rate ratios (IRR) for each cancer type between Japan and England (England reference), adjusted for time period and age group. Incidence rates for leukemias (IRR = 0.9, \[95% CI 0.9‐1.0\], *P* \< .01), acute lymphoblastic leukemias (ALL) (IRR = 0.8, \[0.7‐0.8\], *P* \< .01), lymphomas (IRR = 0.7, \[0.7‐0.8\], *P* \< .01), Hodgkin lymphomas (HL; IRR = 0.1, \[0.1‐0.2\], *P* \< .01), malignant CNS tumors (IRR = 0.8, \[0.7‐0.8\], *P* \< .01), astrocytoma (IRR = 0.6, \[0.6‐0.7\], *P* \< .01), medulloblastoma (IRR = 0.7, \[0.6‐0.8\], *P* \< .01), renal tumors (IRR = 0.4, \[0.3‐0.5\], *P* \< .01), malignant bone tumors (IRR = 0.8, \[0.7‐0.9\], *P* \< .01), Ewing sarcoma family of tumors (Ewing sarcomas, in both bone and soft tissue; IRR = 0.5, \[0.4‐0.7\], *P* \< .01), soft tissue sarcomas (IRR = 0.8, \[0.7‐0.9\], *P* \< .01), rhabdomyosarcomas (IRR = 0.7, \[0.6‐0.8\], *P* \< .01) and other carcinomas (IRR = 0.7, \[0.6‐0.9\], *P* \< .01) were significantly higher in England than Japan. Moreover, incidence rates for HL, renal tumors and Ewing sarcomas in England were over twice as high as those in Japan. Incidence rates for acute myeloid leukemias (AML; IRR = 1.5, \[1.3‐1.6\], *P* \< .01), chronic myeloid leukemias (CML, IRR = 1.4, \[1.0‐1.9\], *P* = .044), NBL (IRR = 1.7, \[1.5‐1.8\], *P* \< .01), hepatic tumors (IRR = 1.7, \[1.4‐2.1\], *P* \< .01) and GCT (IRR = 1.8, \[1.6‐2.1\], *P* \< .01) were significantly higher in Japan than England. Incidence rates for non‐Hodgkin lymphomas (NHL), NBL (children aged 1‐14 years), retinoblastoma, osteosarcomas and soft tissue sarcomas (excluding RMS and Ewing sarcomas) were similar in Japan and England, and the differences were non‐significant. Incidence rates of unspecified subtypes in each cancer group were higher in Japan than in England for leukemias (IRR = 2.1, \[1.6‐2.7\], *P* \< .01), lymphomas (IRR = 1.7, \[1.3‐2.2\], *P* \< .01), CNS tumors (IRR = 2.8, \[2.2‐3.5\], *P* \< .01) and GCT (IRR = 2.2 \[1.1‐4.5\], *P* = .02).

###### 

Age‐standardized incidence rate (ASR) and incidence rate ratio (IRR, England reference) of childhood cancer (age 0‐14 y) in Japan and England, 1993‐2010

                                                                                 Japan   England   IRR               \[95%CI\]   *P*‐value                                          
  ------------------------------------------------------------------------------ ------- --------- ----------------- ----------- ----------- ----------------- ------ ------------- -------
  I. Leukemias                                                                   1794    42.0      \[40‐44\]         7391        46.8        \[45.7‐47.8\]     0.9    \[0.9‐1\]     \<.01
  ALL                                                                            1156    27.3      \[25.7‐28.8\]     5766        36.7        \[35.7‐37.6\]     0.8    \[0.7‐0.8\]   \<.01
  AML                                                                            474     10.9      \[9.9‐11.9\]      1203        7.4         \[7‐7.9\]         1.5    \[1.3‐1.6\]   \<.01
  CML                                                                            53      1.1       \[0.8‐1.5\]       139         0.8         \[0.7‐0.9\]       1.4    \[1‐1.9\]     .044
  Unspecified leukemias                                                          81      2.0       \[1.5‐2.4\]       147         0.9         \[0.8‐1.1\]       2.1    \[1.6‐2.7\]   \<.01
  II\. Lymphomas                                                                 509     11.1      \[10.2‐12.1\]     2481        14.1        \[13.5‐14.6\]     0.8    \[0.7‐0.8\]   \<.01
  Hodgkin lymphomas                                                              38      0.8       \[0.5‐1\]         1039        5.6         \[5.3‐6\]         0.1    \[0.1‐0.2\]   \<.01
  Non‐Hodgkin lymphomas[a](#cas13457-note-0009){ref-type="fn"}                   321     6.9       \[6.1‐7.7\]       1157        6.7         \[6.3‐7.1\]       1.0    \[0.9‐1.2\]   .7
  Unspecified lymphomas                                                          92      2.0       \[1.6‐2.4\]       188         1.1         \[0.9‐1.3\]       1.7    \[1.3‐2.2\]   \<.01
  III\. CNS tumors                                                               796     18.0      \[16.7‐19.3\]     3719        22.8        \[22‐23.5\]       0.8    \[0.7‐0.9\]   \<.01
  Astrocytoma                                                                    210     4.5       \[3.9‐5.1\]       1222        7.4         \[7‐7.8\]         0.6    \[0.6‐0.7\]   \<.01
  Medulloblastoma                                                                184     4.2       \[3.6‐4.9\]       1031        6.3         \[5.9‐6.7\]       0.7    \[0.6‐0.8\]   \<.01
  Unspecified CNS tumors                                                         129     2.9       \[2.4‐3.4\]       173         1.1         \[0.9‐1.2\]       2.8    \[2.2‐3.5\]   \<.01
  IV\. Neuroblastoma                                                             604     16.2      \[14.9‐17.5\]     1405        9.6         \[9.1‐10.1\]      1.7    \[1.5‐1.8\]   \<.01
  NBL children aged 1‐14 y                                                       268     7.5       \[6.6‐8.4\]       971         7.1         \[6.6‐7.5\]       1.1    \[0.9‐1.2\]   .46
  V. Retinoblastoma                                                              170     4.6       \[3.9‐5.3\]       647         4.5         \[4.2‐4.9\]       1.0    \[0.9‐1.2\]   .78
  VI\. Renal tumors                                                              135     3.5       \[2.9‐4.1\]       1332        8.9         \[8.5‐9.4\]       0.4    \[0.3‐0.5\]   \<.01
  VII\. Hepatic tumors                                                           113     2.9       \[2.4‐3.5\]       256         1.7         \[1.5‐1.9\]       1.7    \[1.4‐2.1\]   \<.01
  VIII\. Malignant bone tumors                                                   233     4.5       \[3.9‐5.1\]       1044        5.7         \[5.3‐6\]         0.8    \[0.7‐0.9\]   \<.01
  Osteosarcomas                                                                  148     2.8       \[2.4‐3.3\]       558         3.0         \[2.7‐3.2\]       1.0    \[0.8‐1.1\]   .57
  Ewing sarcomas (bone and soft tissue)[b](#cas13457-note-0010){ref-type="fn"}   76      1.5       \[1.2‐1.9\]       518         2.9         \[2.6‐3.1\]       0.5    \[0.4‐0.7\]   \<.01
  Unspecified malignant bone tumors                                              9       0.2       \[0.1‐0.3\]       49          0.3         \[0.2‐0.4\]       0.7    \[0.3‐1.4\]   .26
  IX\. Soft tissue sarcomas                                                      295     6.6       \[5.9‐7.4\]       1449        8.8         \[8.4‐9.3\]       0.8    \[0.7‐0.9\]   \<.01
  Rhabdomyosarcomas (RMS)                                                        148     3.4       \[2.8‐3.9\]       788         5.0         \[4.6‐5.3\]       0.7    \[0.6‐0.8\]   \<.01
  Soft tissue sarcomas (excluding RMS and Ewing sarcomas)                        124     2.8       \[2.3‐3.3\]       536         3.1         \[2.9‐3.4\]       0.9    \[0.7‐1\]     .122
  Unspecified soft tissue sarcomas                                               22      0.5       \[0.3‐0.7\]       127         0.7         \[0.6‐0.9\]       0.6    \[0.4‐1.0\]   .05
  X. Germ cell tumors                                                            359     7.8       \[7‐8.6\]         724         4.3         \[4‐4.7\]         1.8    \[1.6‐2.1\]   \<.01
  Unspecified malignant gonadal tumors                                           13      0.3       \[0.1‐0.4\]       21          0.1         \[0.1‐0.2\]       2.2    \[1.1‐4.5\]   .02
  XI\. Other carcinomas                                                          132     2.6       \[2.1‐3\]         646         3.6         \[3.3‐3.8\]       0.7    \[0.6‐0.9\]   \<.01
  XI\. Unspecified cancers                                                       52      1.2       \[0.9‐1.5\]       201         1.2         \[1.1‐1.4\]       n.a.                 
  Total                                                                          5192    121.1     \[117.8‐124.5\]   21295       132.0       \[130.2‐133.7\]   0.9    \[0.9‐0.9\]   \<.01

ALL, acute lymphoblastic leukemias; AML, acute myeloid leukemias, CML, chronic myeloid leukemia; CNS, central nervous system; NBL, neuroblastoma. IRR were adjusted for time period and age group (using England as the reference). n.a., IRR of "unspecified cancers" (ICCC‐3 group XII) were not calculated because models were not fitted.

This includes Burkitt lymphoma.

Ewing sarcoma family of tumors, in both bone and soft tissue.
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We analyzed age‐specific incidence rates by sex for some solid tumors (Wilms tumor, hepatoblastoma and GCT of each site) in each country (Table [S2](#cas13457-sup-0001){ref-type="supplementary-material"} and Figure [S2](#cas13457-sup-0001){ref-type="supplementary-material"}). The peak age for Wilms tumor in Japan was infants aged under 1 year, whereas in England it was children aged 1‐4 years. Hepatoblastoma was the most common type of hepatic tumor in both countries (N = 100 \[88%\] in Japan vs N = 211 \[82%\] in England) and the age distribution was similar between countries. Age‐specific incidence rates for intracranial GCT were higher in Japan than in England for all age groups. Incidence of gonadal GCT in male infants in Japan was much higher than in England. However, the numbers were too small to perform any relevant statistical comparison.

3.4. Trends in survival for each cancer type in Japan and England {#cas13457-sec-0009}
-----------------------------------------------------------------

We analyzed trends in 1‐year, 5‐year and 10‐year survival for each cancer type and each period in both countries (Table[4](#cas13457-tbl-0004){ref-type="table"}). One‐year survival was over 80% in most cancers in both countries in the period 2005‐2008, except for hepatic tumors (76%) in Japan and AML (79%) and CNS tumors (75%) in England. Five‐year survival for leukemias significantly improved from 1993‐1996 to 2005‐2008, reaching over 80% in 2005‐2008 in both countries (Japan: 71% \[95% CI 67‐75\] to 83% \[79‐86\], England: 76% \[74‐78\] to 88% \[86‐90\]), whereas 5‐year survival for CNS tumors remained at 50% in both countries. Ten‐year survival was over 80% for ALL (children aged 1‐14 years), CML, lymphomas, NBL infants (age \<1 year), retinoblastoma, renal tumors and germ cell tumors in both countries. To calculate 10‐year survival in recent periods, we used a different approach (period approach) from the cohort approach, so there was divergence between 5‐year survival and 10‐year survival (higher survival in 10‐year survival than 5‐year survival) in some cancers (lymphomas, NBL, renal tumors, and unspecified cancers in Japan, and AML, CML, NBL infants, and GCT in England). Figure [2](#cas13457-fig-0002){ref-type="fig"} illustrates 5‐year survival for most types of childhood cancers in Japan and England in 1993‐1996 and in 2005‐2008. Difference in 5‐year survival between countries narrowed from 1993‐1996 to 2005‐2008 for CML, lymphomas, CNS tumors, retinoblastoma, soft tissue sarcomas and RMS. In contrast, 5‐year survival was still less than 80% in both countries even in the most recent period for AML (Japan: 78%, England: 66%), CNS tumors (Japan: 59%, England: 57%), NBL children aged 1‐14 years (Japan: 75%, England: 57%), malignant bone tumors (Japan: 67%, England: 65%), soft tissue sarcomas (Japan: 68%, England: 73%) and RMS (Japan: 59%, England: 70%). Figure [3](#cas13457-fig-0003){ref-type="fig"} shows the changes in 5‐year survival for each cancer type (except for other carcinomas and unspecified cancers) in each country from 1993‐1996 to 2005‐2008. Five‐year survival improved for most cancers except for renal tumors in Japan, and CNS tumors and NBL infants in England. Survival for CML dramatically improved in both countries (Japan: 67% to 100%, England: 44% to 84%).

###### 

Overall 1‐y, 5‐y and 10‐y survival of childhood cancer (age 0‐14 y) by period of diagnosis and cancer type in Japan and England

                                 Japan   England                                                                                                                                     
  ------------------------------ ------- --------- --------------- ------ --------------- -------- ------------------- ------ ------ --------------- ------ --------------- -------- -------------------
  I. Leukemias                                                                                                                                                                       
  1993‐1996                      442     89.3      \[86‐91.8\]     71.2   \[66.7‐75.2\]   67.8     \[63.2‐72\]         1564   91.0   \[89.5‐92.4\]   76.0   \[73.8‐78.1\]   70.4     \[68‐72.6\]
  1997‐2000                      355     94.6      \[91.7‐96.5\]   77.7   \[73‐81.7\]     74.5     \[69.6‐78.7\]       1627   91.3   \[89.8‐92.5\]   78.5   \[76.4‐80.4\]   76.0     \[73.9‐78\]
  2001‐2004                      371     93.7      \[90.7‐95.8\]   80.1   \[75.7‐83.9\]   *73.8*   *\[68.8*‐*78.2\]*   1630   92.8   \[91.4‐93.9\]   84.2   \[82.3‐85.9\]   82.3     \[80.4‐84.1\]
  2005‐2008                      369     94.7      \[91.8‐96.6\]   82.9   \[78.5‐86.4\]   *79.8*   *\[75.2*‐*83.6\]*   1518   94.3   \[93‐95.4\]     88.1   \[86.3‐89.6\]   *84.6*   *\[82.7*‐*86.3\]*
  ALL children aged 1‐14 y                                                                                                                                                           
  1993‐1996                      269     92.5      \[88.6‐95.1\]   79.2   \[73.8‐83.6\]   74.1     \[68.4‐79\]         1195   95.7   \[94.4‐96.7\]   82.8   \[80.6‐84.9\]   76.8     \[74.3‐79.1\]
  1997‐2000                      224     96.8      \[93.5‐98.5\]   82.8   \[77.2‐87.2\]   79.1     \[73.1‐83.9\]       1226   94.6   \[93.2‐95.7\]   84.1   \[81.9‐86\]     81.3     \[79‐83.4\]
  2001‐2004                      236     97.0      \[93.8‐98.5\]   85.7   \[80.4‐89.6\]   *77.1*   *\[70.8*‐*82.1\]*   1222   95.3   \[94‐96.4\]     88.9   \[87‐90.6\]     86.9     \[84.8‐88.6\]
  2005‐2008                      225     97.3      \[94‐98.8\]     86.8   \[81.6‐90.6\]   *84.1*   *\[78.5*‐*88.3\]*   1155   97.6   \[96.5‐98.3\]   93.2   \[91.5‐94.5\]   *88.8*   *\[86.8*‐*90.5\]*
  AML                                                                                                                                                                                
  1993‐1996                      104     86.4      \[78.1‐91.7\]   62.1   \[52‐70.7\]     61.1     \[51‐69.7\]         258    75.6   \[69.9‐80.4\]   55.0   \[48.8‐60.9\]   51.5     \[45.3‐57.4\]
  1997‐2000                      94      91.4      \[83.6‐95.6\]   68.6   \[58‐77\]       67.5     \[56.9‐76\]         256    82.0   \[76.8‐86.2\]   63.3   \[57.1‐68.9\]   61.7     \[55.5‐67.4\]
  2001‐2004                      95      88.1      \[79.6‐93.3\]   66.4   \[55.7‐75\]     *64.9*   *\[53.5*‐*74.2\]*   270    84.4   \[79.5‐88.3\]   66.6   \[60.7‐71.9\]   65.2     \[59.1‐70.5\]
  2005‐2008                      101     93.7      \[86.6‐97.1\]   77.9   \[68.1‐85\]     *72.6*   *\[62.1*‐*80.7\]*   216    79.2   \[73.1‐84\]     66.2   \[59.5‐72.1\]   *68.1*   *\[61.8*‐*73.6\]*
  CML                                                                                                                                                                                
  1993‐1996                      21      90.5      \[67‐97.5\]     66.7   \[42.5‐82.5\]   66.7     \[42.5‐82.5\]       23     73.9   \[50.9‐87.3\]   43.5   \[23.3‐62.1\]   34.8     \[16.6‐53.7\]
  1997‐2000                      11      90.9      \[50.8‐98.7\]   72.7   \[37.1‐90.3\]   54.5     \[22.9‐78\]         42     73.8   \[57.7‐84.6\]   52.4   \[36.4‐66.1\]   52.4     \[36.4‐66.1\]
  2001‐2004                      11      90.9      \[50.8‐98.7\]   81.8   \[44.7‐95.1\]   *66.3*   *\[32.9*‐*85.9\]*   32     90.6   \[73.7‐96.9\]   84.4   \[66.5‐93.2\]   81.3     \[62.9‐91.1\]
  2005‐2008                      8       100                       100                    *87.5*   *\[38.7*‐*98.1\]*   25     100                    84.0   \[62.8‐93.7\]   *88.7*   *\[69*‐*96.2\]*
  II\. Lymphomas                                                                                                                                                                     
  1993‐1996                      130     80.5      \[72.6‐86.4\]   72.7   \[64.1‐79.6\]   71.9     \[63.3‐78.9\]       480    90.4   \[87.4‐92.7\]   82.3   \[78.6‐85.4\]   80.6     \[76.8‐83.9\]
  1997‐2000                      104     96.1      \[89.9‐98.5\]   89.1   \[81.2‐93.8\]   87.2     \[78.9‐92.3\]       562    91.8   \[89.2‐93.8\]   87.2   \[84.1‐89.7\]   85.8     \[82.6‐88.4\]
  2001‐2004                      105     94.2      \[87.6‐97.4\]   90.4   \[82.9‐94.7\]   *87.4*   *\[79.2*‐*92.5\]*   528    92.2   \[89.6‐94.2\]   88.1   \[85‐90.6\]     86.5     \[83.3‐89.2\]
  2005‐2008                      102     92.9      \[85.7‐96.5\]   86.8   \[78.3‐92.1\]   *87.9*   *\[79.7*‐*93\]*     571    95.8   \[93.8‐97.2\]   91.2   \[88.6‐93.3\]   *90.1*   *\[87.3*‐*92.4\]*
  III\. CNS tumors                                                                                                                                                                   
  1993‐1996                      168     77.9      \[70.8‐83.4\]   50.9   \[43.1‐58.2\]   44.8     \[37.2‐52.2\]       818    78.5   \[75.5‐81.1\]   59.6   \[56.2‐62.9\]   55.8     \[52.3‐59.1\]
  1997‐2000                      155     80.6      \[73.5‐86\]     60.6   \[52.5‐67.8\]   53.2     \[45‐60.7\]         783    74.1   \[70.9‐77\]     57.8   \[54.3‐61.2\]   52.7     \[49.1‐56.1\]
  2001‐2004                      159     80.3      \[73.2‐85.7\]   56.7   \[48.6‐64\]     *51.8*   *\[43*‐*59.9\]*     794    77.8   \[74.8‐80.6\]   58.1   \[54.5‐61.4\]   53.5     \[50‐56.9\]
  2005‐2008                      163     84.3      \[77.6‐89.1\]   58.9   \[50.8‐66.1\]   *51.8*   *\[43.8*‐*59.2\]*   769    75.3   \[72.1‐78.2\]   57.2   \[53.6‐60.6\]   *52.3*   *\[48.7*‐*55.7\]*
  IV\. Neuroblastoma                                                                                                                                                                 
  1993‐1996                      203     96.0      \[92.2‐98\]     85.1   \[79.4‐89.4\]   84.1     \[78.3‐88.5\]       299    84.3   \[79.6‐87.9\]   57.8   \[52‐63.2\]     56.8     \[51‐62.2\]
  1997‐2000                      126     92.9      \[86.7‐96.2\]   83.3   \[75.6‐88.8\]   79.1     \[70.9‐85.3\]       311    85.9   \[81.5‐89.3\]   62.0   \[56.3‐67.1\]   58.7     \[53‐64\]
  2001‐2004                      147     96.6      \[91.9‐98.6\]   87.6   \[81‐92\]       *84.2*   *\[77*‐*89.3\]*     313    87.9   \[83.7‐91\]     64.9   \[59.3‐69.9\]   61.7     \[56‐66.8\]
  2005‐2008                      71      97.1      \[88.7‐99.3\]   79.3   \[67.6‐87.2\]   *85.4*   *\[77*‐*90.8\]*     278    90.3   \[86.2‐93.2\]   65.0   \[59.1‐70.3\]   *63.2*   *\[57.4*‐*68.4\]*
  NBL infants (age \<1 y)                                                                                                                                                            
  1993‐1996                      140     97.9      \[93.5‐99.3\]   97.1   \[92.6‐98.9\]   97.1     \[92.6‐98.9\]       83     92.8   \[84.6‐96.7\]   86.7   \[77.3‐92.4\]   86.7     \[77.3‐92.4\]
  1997‐2000                      85      95.3      \[87.9‐98.2\]   92.9   \[85‐96.8\]     91.7     \[83.3‐95.9\]       84     89.3   \[80.4‐94.3\]   83.3   \[73.4‐89.8\]   83.3     \[73.4‐89.8\]
  2001‐2004                      75      100                       98.6   \[90.8‐99.8\]   *96.6*   *\[89.8*‐*98.9\]*   116    94.0   \[87.8‐97.1\]   90.5   \[83.5‐94.6\]   90.5     \[83.5‐94.6\]
  2005‐2008                      14      100                       100                    *98.9*   *\[92.5*‐*99.8\]*   88     88.6   \[79.9‐93.7\]   82.9   \[73.3‐89.3\]   *87.4*   *\[78.9*‐*92.7\]*
  NBL children aged 1‐14 y                                                                                                                                                           
  1993‐1996                      63      91.9      \[81.7‐96.6\]   58.1   \[44.8‐69.2\]   54.8     \[41.7‐66.2\]       216    81.0   \[75.1‐85.6\]   46.8   \[40‐53.2\]     45.4     \[38.6‐51.9\]
  1997‐2000                      41      87.8      \[73.2‐94.7\]   63.4   \[46.8‐76.1\]   53.4     \[37‐67.2\]         227    84.6   \[79.2‐88.7\]   54.2   \[47.5‐60.4\]   49.7     \[43.1‐56\]
  2001‐2004                      72      93.0      \[83.9‐97\]     76.1   \[64.3‐84.4\]   *62.1*   *\[46.7*‐*74.3\]*   197    84.3   \[78.4‐88.7\]   49.7   \[42.6‐56.5\]   44.7     \[37.6‐51.5\]
  2005‐2008                      57      96.4      \[86.2‐99.1\]   74.5   \[60.8‐84.1\]   *73.4*   *\[57.9*‐*84\]*     190    91.1   \[86‐94.3\]     56.7   \[49.3‐63.4\]   *50.3*   *\[43.1*‐*57.1\]*
  V. Retinoblastoma                                                                                                                                                                  
  1993‐1996                      38      100                       89.5   \[74.3‐95.9\]   89.5     \[74.3‐95.9\]       149    99.3   \[95.3‐99.9\]   96.6   \[92.1‐98.6\]   96.6     \[92.1‐98.6\]
  1997‐2000                      31      96.8      \[79.2‐99.5\]   96.8   \[79.2‐99.5\]   93.5     \[76.6‐98.3\]       129    96.9   \[91.9‐98.8\]   94.5   \[88.9‐97.4\]   94.5     \[88.9‐97.4\]
  2001‐2004                      41      100                       95.1   \[81.9‐98.8\]   *91.6*   *\[76.1*‐*97.2\]*   133    99.2   \[94.8‐99.9\]   98.5   \[94.1‐99.6\]   98.5     \[94.1‐99.6\]
  2005‐2008                      37      100                       100                    *100*                        137    100                    100                    *99.2*   *\[94.7*‐*99.9\]*
  VI\. Renal tumors                                                                                                                                                                  
  1993‐1996                      33      93.9      \[77.9‐98.4\]   84.7   \[67.1‐93.4\]   81.6     \[63.5‐91.3\]       282    90.4   \[86.3‐93.3\]   81.2   \[76.1‐85.3\]   80.5     \[75.4‐84.7\]
  1997‐2000                      29      93.1      \[75.1‐98.2\]   86.2   \[67.3‐94.6\]   86.2     \[67.3‐94.6\]       274    94.9   \[91.5‐96.9\]   89.8   \[85.5‐92.8\]   88.3     \[83.9‐91.6\]
  2001‐2004                      32      100                       87.0   \[68.9‐94.9\]   *86.3*   *\[67.4*‐*94.6\]*   307    93.1   \[89.7‐95.5\]   85.6   \[81.2‐89.1\]   85.6     \[81.2‐89.1\]
  2005‐2008                      24      100                       82.6   \[60.1‐93.1\]   *86.5*   *\[68*‐*94.7\]*     299    92.6   \[89‐95.1\]     85.2   \[80.6‐88.8\]   *84.1*   *\[79.5*‐*87.7\]*
  VII\. Hepatic tumors                                                                                                                                                               
  1993‐1996                      15      80.0      \[50‐93.1\]     73.3   \[43.6‐89.1\]   58.3     \[29.3‐78.9\]       50     82.0   \[68.3‐90.2\]   70.0   \[55.3‐80.7\]   70.0     \[55.3‐80.7\]
  1997‐2000                      28      73.8      \[52.6‐86.6\]   58.2   \[37.3‐74.3\]   58.2     \[37.3‐74.3\]       48     79.2   \[64.7‐88.2\]   64.6   \[49.4‐76.3\]   60.4     \[45.2‐72.6\]
  2001‐2004                      25      96.0      \[74.8‐99.4\]   92.0   \[71.6‐97.9\]   *73.8*   *\[44.8*‐*89.1\]*   65     83.1   \[71.5‐90.2\]   69.2   \[56.5‐78.9\]   64.6     \[51.7‐74.9\]
  2005‐2008                      25      76.0      \[54.2‐88.4\]   76.0   \[54.2‐88.4\]   *75.9*   *\[54*‐*88.4\]*     55     87.3   \[75.1‐93.7\]   81.8   \[68.8‐89.8\]   *75.3*   *\[61.3*‐*84.9\]*
  VIII\. Malignant bone tumors                                                                                                                                                       
  1993‐1996                      47      87.2      \[73.8‐94.1\]   61.7   \[46.3‐73.9\]   57.0     \[41.5‐69.7\]       212    92.5   \[88‐95.3\]     61.8   \[54.9‐68\]     55.7     \[48.7‐62\]
  1997‐2000                      58      94.6      \[84.3‐98.2\]   67.9   \[53.9‐78.4\]   62.1     \[48‐73.5\]         206    88.3   \[83.1‐92\]     66.0   \[59.1‐72\]     59.2     \[52.2‐65.6\]
  2001‐2004                      51      94.0      \[82.5‐98\]     72.0   \[57.4‐82.4\]   *65.0*   *\[50.1*‐*76.4\]*   231    93.9   \[90‐96.4\]     58.9   \[52.2‐64.9\]   55.0     \[48.3‐61.1\]
  2005‐2008                      43      93.0      \[79.9‐97.7\]   67.4   \[51.3‐79.3\]   *63.3*   *\[47.9*‐*75.3\]*   225    92.4   \[88.1‐95.2\]   64.9   \[58.3‐70.7\]   *58.2*   *\[51.2*‐*64.6\]*
  IX\. Soft tissue sarcomas                                                                                                                                                          
  1993‐1996                      64      89.1      \[78.4‐94.6\]   57.8   \[44.8‐68.8\]   53.0     \[40.1‐64.4\]       320    90.6   \[86.9‐93.3\]   69.0   \[63.6‐73.7\]   66.4     \[60.9‐71.3\]
  1997‐2000                      63      88.7      \[77.8‐94.5\]   61.3   \[48‐72.1\]     59.6     \[46.4‐70.6\]       294    87.1   \[82.7‐90.4\]   66.7   \[61‐71.7\]     62.9     \[57.1‐68.2\]
  2001‐2004                      61      95.0      \[85.3‐98.4\]   70.0   \[56.7‐79.9\]   *65.6*   *\[52.5*‐*76\]*     319    85.6   \[81.2‐89\]     63.1   \[57.6‐68.2\]   60.6     \[55‐65.7\]
  2005‐2008                      58      85.7      \[73.5‐92.6\]   67.9   \[53.9‐78.4\]   *56.3*   *\[43*‐*67.7\]*     297    87.2   \[82.8‐90.5\]   72.9   \[67.4‐77.6\]   *63.2*   *\[57.5*‐*68.4\]*
  Rhabdomyosarcoma                                                                                                                                                                   
  1993‐1996                      36      88.9      \[73.1‐95.7\]   41.7   \[25.6‐57\]     38.7     \[23.1‐54.1\]       199    91.5   \[86.6‐94.6\]   67.6   \[60.6‐73.7\]   67.1     \[60.1‐73.2\]
  1997‐2000                      36      86.1      \[69.8‐94\]     47.2   \[30.5‐62.3\]   44.4     \[28‐59.6\]         164    86.6   \[80.3‐91\]     65.9   \[58.1‐72.6\]   62.8     \[54.9‐69.7\]
  2001‐2004                      35      94.1      \[78.5‐98.5\]   64.7   \[46.3‐78.2\]   *57.2*   *\[37.8‐72.5\]*     164    86.6   \[80.3‐91\]     56.5   \[48.6‐63.7\]   54.7     \[46.7‐61.9\]
  2005‐2008                      22      86.4      \[63.4‐95.4\]   59.1   \[36.1‐76.2\]   *48.5*   *\[29.9‐64.8\]*     157    88.5   \[82.3‐92.6\]   70.3   \[62.4‐76.8\]   *56.8*   *\[48.7‐64\]*
  X. Germ cell tumors                                                                                                                                                                
  1993‐1996                      80      92.5      \[84‐96.6\]     84.9   \[74.9‐91.1\]   84.9     \[74.9‐91.1\]       151    94.0   \[88.9‐96.9\]   86.8   \[80.2‐91.2\]   85.4     \[78.7‐90.2\]
  1997‐2000                      80      95.0      \[87.1‐98.1\]   91.2   \[82.3‐95.7\]   89.9     \[80.8‐94.8\]       142    96.5   \[91.7‐98.5\]   89.4   \[83‐93.5\]     89.4     \[83‐93.5\]
  2001‐2004                      73      98.6      \[90.2‐99.8\]   95.7   \[87.1‐98.6\]   *95.2*   *\[85.7‐98.4\]*     151    98.0   \[94‐99.4\]     93.4   \[88‐96.4\]     92.7     \[87.2‐95.9\]
  2005‐2008                      67      96.9      \[88.1‐99.2\]   95.3   \[86‐98.4\]     *92.1*   *\[82‐96.7\]*       173    96.0   \[91.7‐98.1\]   93.6   \[88.8‐96.4\]   *93.8*   *\[88.8‐96.6\]*
  XI\. Other carcinomas                                                                                                                                                              
  1993‐1996                      29      93.1      \[75.1‐98.2\]   89.7   \[71.3‐96.5\]   86.1     \[67‐94.5\]         127    94.5   \[88.8‐97.3\]   85.8   \[78.5‐90.8\]   83.5     \[75.8‐88.9\]
  1997‐2000                      27      96.3      \[76.5‐99.5\]   92.6   \[73.5‐98.1\]   84.8     \[64.5‐94\]         126    92.9   \[86.7‐96.2\]   83.3   \[75.6‐88.8\]   81.7     \[73.8‐87.5\]
  2001‐2004                      31      96.6      \[77.9‐99.5\]   86.2   \[67.3‐94.6\]   *82.8*   *\[63.4‐92.5\]*     147    94.5   \[89.4‐97.2\]   87.7   \[81.2‐92.1\]   87.0     \[80.4‐91.5\]
  2005‐2008                      23      85.0      \[60.4‐94.9\]   80.0   \[55.1‐92\]     *75.6*   *\[53.5‐88.2\]*     151    92.7   \[87.2‐95.9\]   89.4   \[83.2‐93.3\]   *88.0*   *\[81.7‐92.3\]*
  XII\. Unspecified cancers                                                                                                                                                          
  1993‐1996                      7       100                       83.3   \[27.3‐97.5\]   83.3     \[27.3‐97.5\]       50     90.0   \[77.6‐95.7\]   85.9   \[72.7‐93\]     85.9     \[72.7‐93\]
  1997‐2000                      13      92.3      \[56.6‐98.9\]   76.9   \[44.2‐91.9\]   69.2     \[37.3‐87.2\]       33     87.9   \[70.9‐95.3\]   78.8   \[60.6‐89.3\]   75.8     \[57.3‐87.1\]
  2001‐2004                      12      91.7      \[53.9‐98.8\]   83.3   \[48.2‐95.6\]   *79.3*   *\[48.5‐92.9\]*     25     84.0   \[62.8‐93.7\]   72.0   \[50.1‐85.5\]   72.0     \[50.1‐85.5\]
  2005‐2008                      5       80.0      \[20.4‐96.9\]   60.0   \[12.6‐88.2\]   *66.3*   *\[26.6‐88\]*       50     100                    89.8   \[77.2‐95.6\]   *89.2*   *\[69.4‐96.5\]*

Cohort approach (1‐y and 5‐y overall survival \[OS\] in 1993‐2008 in both countries, 10‐y OS in 1993‐2000 in Japan and in 1993‐2004 in England) and *period approach (10‐y OS in 2001‐2008 in Japan and in 2005‐2008 in England)*. ALL, acute lymphoblastic leukemias; AML, acute myeloid leukemias; CML, chronic myeloid leukemia; CNS, central nervous system; NBL, neuroblastoma.

John Wiley & Sons, Ltd

![Five‐year survival for each cancer type in Japan and England, 1993‐1996 and 2005‐2008. Five‐year survival for some major diagnostic groups in Japan and England are plotted on the same graphic for each period. ALL, acute lymphoblastic leukemias; AML, acute myeloid leukemias; CML, chronic myeloid leukemia; CNS, central nervous system; NBL, neuroblastoma; RMS, rhabdomyosarcoma](CAS-109-422-g002){#cas13457-fig-0002}

![Change in 5‐y survival for each cancer type from 1993‐1996 to 2005‐2008, in Japan and England. ALL, acute lymphoblastic leukemias; AML, acute myeloid leukemias; CML, chronic myeloid leukemia; CNS, central nervous system GCTs, germ cell tumors; NBL, neuroblastoma; RMS, rhabdomyosarcoma](CAS-109-422-g003){#cas13457-fig-0003}

4. DISCUSSION {#cas13457-sec-0010}
=============

In this study, we compared incidence and trends in survival for each childhood cancer type in Japan and England. Incidence of all childhood cancers combined decreased in Japan throughout 1993‐2010 (Table [2](#cas13457-tbl-0002){ref-type="table"}, Figure [S1](#cas13457-sup-0001){ref-type="supplementary-material"}), whereas in England incidence for all cancers combined was stable from 1999‐2004 to 2005‐2010, after a slight increase in the earlier period. However, analysis of the incidence by cancer type showed that the trends in cancer‐specific incidence hardly varied in each county, except for neuroblastoma in Japan (Table [2](#cas13457-tbl-0002){ref-type="table"}). The apparent drop in incidence for neuroblastoma in Japan was probably due to the cessation of the national screening program for neuroblastoma, which had been conducted as urine tests for all infants at 6 months of age since 1985.[20](#cas13457-bib-0020){ref-type="ref"}, [21](#cas13457-bib-0021){ref-type="ref"} The Ministry of Health, Labour and Welfare terminated the program in 2004 on the basis of the self‐healing potential of infant NBL and the negative effects of screening on mortality.[22](#cas13457-bib-0022){ref-type="ref"} In the most recent period, after the cessation of this screening program in Japan, incidence for all cancers was higher in England than in Japan (ASR 2005‐2010 139 vs 116). The incidence of many cancer types differed between Japan and England. In England, incidence of HL, renal tumors and Ewing sarcomas was more than double that of Japan. Previous studies have shown racial differences in incidence for these cancers.[23](#cas13457-bib-0023){ref-type="ref"}, [24](#cas13457-bib-0024){ref-type="ref"}, [25](#cas13457-bib-0025){ref-type="ref"}, [26](#cas13457-bib-0026){ref-type="ref"}, [27](#cas13457-bib-0027){ref-type="ref"}, [28](#cas13457-bib-0028){ref-type="ref"}, [29](#cas13457-bib-0029){ref-type="ref"} Etiological factors of HL have been suggested by the bimodal age distribution, by elevated risks in males, by the occurrence of Epstein--Barr virus in HL tumor cells, and by identifying inherited susceptibility genes; however, the mechanism by which racial differences in incidence for HL occur is still unclear. Regarding renal tumors, previous studies which reported on differences in age distribution between countries for Wilms tumor showed the peak age for occurrence in East Asia to be infants (age \<1 year), but among Caucasians in the USA the peak occurrence was older.[24](#cas13457-bib-0024){ref-type="ref"}, [25](#cas13457-bib-0025){ref-type="ref"} Our study supports these findings (Table [S2](#cas13457-sup-0001){ref-type="supplementary-material"} and Figure [S2](#cas13457-sup-0001){ref-type="supplementary-material"}). Some other reports show differences in epigenetic factors in Wilms tumor between Japanese and Caucasians.[26](#cas13457-bib-0026){ref-type="ref"}, [27](#cas13457-bib-0027){ref-type="ref"} For Ewing sarcomas, one report showed that Japanese Ewing sarcoma patients have a higher frequency of loss of chromosome 19 than European Caucasian patients.[28](#cas13457-bib-0028){ref-type="ref"} However, these tumors are rare and their etiology has not been sufficiently investigated to explain these differences in incidence.[29](#cas13457-bib-0029){ref-type="ref"} Regarding the higher incidence of AML in Japan, Bessho reported the mis‐classification of ALL to ANLL (AML), which overestimated the proportion of ANLL in the 1970s.[30](#cas13457-bib-0030){ref-type="ref"} However, nowadays, diagnosis of leukemia has become much more accurate and the proportion of unknown leukemia subtype was only approximately 5% in our data (Table [3](#cas13457-tbl-0003){ref-type="table"}). The ALL:AML ratio in our data was 2.4:1, which is similar to that found in the report of the Japanese pediatric leukemia study group (JPLSG), containing information on molecular abnormalities collected by pediatric oncologists (ALL:AML = 2.8:1).[31](#cas13457-bib-0031){ref-type="ref"} On the IICC‐3 website, the ASR of AML was around 10 per million person‐years in Japan and Korea,[32](#cas13457-bib-0032){ref-type="ref"} whereas the figure was around 7 per million person‐years in an Austria‐based study.[19](#cas13457-bib-0019){ref-type="ref"} The CONCORD‐2 study on cancer survival reported higher proportions of AML in Asia than in Europe.[7](#cas13457-bib-0007){ref-type="ref"} In the US data, there are no large racial differences in incidence for AML.[33](#cas13457-bib-0033){ref-type="ref"} Further research will be needed to clarify whether the differences we have observed are due to underlying ethnic difference in the incidence of AML.

When comparing incidence for each subgroup, the proportion of "unspecified" histology within each cancer group should be taken into account (Table [3](#cas13457-tbl-0003){ref-type="table"}). The proportion of "unspecified" lymphomas (ICCC‐3 II‐e; 18%) or "unspecified" CNS tumors (ICCC‐3 III‐f; 16%) in Japan was over 10% within each cancer group in the total period (1993‐2010), although it decreased to under 10% in the most recent periods (data not shown).

Five‐year survival for most cancer types improved in both Japan and England. (Table [4](#cas13457-tbl-0004){ref-type="table"}). For example, survival of childhood leukemias improved constantly in both countries throughout 1993‐2008. Risk stratification and improvement in clinical trials/treatment may have contributed to the improvement in survival for ALL (children aged 1‐14 years) and AML in both countries.[31](#cas13457-bib-0031){ref-type="ref"}, [34](#cas13457-bib-0034){ref-type="ref"}, [35](#cas13457-bib-0035){ref-type="ref"}, [36](#cas13457-bib-0036){ref-type="ref"} Survival in CML improved dramatically in both countries after the introduction of the tyrosine kinase inhibitor (TKI) imatinib (trade name Gleevec) approved by the US FDA, Japan and the UK in 2001 (Figure [3](#cas13457-fig-0003){ref-type="fig"}).[37](#cas13457-bib-0037){ref-type="ref"} This is an impressive example of an effective therapy changing the survival of patients dramatically. For survivors, however, careful, long‐term follow‐up is needed because several case reports have described growth impairment of pediatric CML patients as an adverse effect of imatinib.[38](#cas13457-bib-0038){ref-type="ref"}, [39](#cas13457-bib-0039){ref-type="ref"} Differences in 5‐year survival in some cancer types (CML, lymphomas, CNS tumors, retinoblastoma, soft tissue sarcomas and rhabdomyosarcoma) between countries seem to be narrowing (Figure [2](#cas13457-fig-0002){ref-type="fig"}). This may be the result of recent international collaboration between countries. However, even for the most recent periods, 5‐year survival for several cancer types (AML, CNS tumors, NBL \[children aged 1‐14 years\], soft tissue sarcomas, malignant bone tumors) remains \<80% in both countries. To improve survival for patients with these cancer types, we should target research at developing new drugs and improving treatment protocols. Five‐year survival of renal tumors in Japan, NBL under 1 year of age and CNS tumors in England decreased in the more recent period (Figure [3](#cas13457-fig-0003){ref-type="fig"}). One possible reason for the latter is that more cases of pilocytic astrocytoma could have been coded and classified as astrocytoma NOS or glioma NOS (both with the malignant behavior code) in the earlier years.

4.1. Cancer strategy for childhood cancer {#cas13457-sec-0011}
-----------------------------------------

Since 1974, the Japanese Government has subsidized medical expenses for children and adolescents under 18 years of age with cancer.[40](#cas13457-bib-0040){ref-type="ref"} The *National Cancer Control Act* in Japan was established in 2006, initially focusing on major adult cancers. The second cancer control plan in 2012 first raised the issue of care for children and young cancer patients. Fifteen hospitals were designated as childhood cancer care hospitals in 2012 to increase centralization and cooperation between all the hospitals in Japan.

In the UK, the first National Health Service cancer control plan started in 2000. "Improving outcomes in children and young people with cancer" was published as national guidance for cancer services by the National Institute for Health and Clinical Excellence in 2005. There are 20 specialized hospitals for childhood cancer, known as principal treatment centers, and over 80 shared care centers, known as Paediatric Oncology Shared Care Units. In Europe, similar but less detailed standards of care for children with cancer were published in 2013,[41](#cas13457-bib-0041){ref-type="ref"} with an international survey of the extent of their implementation published in 2016.[42](#cas13457-bib-0042){ref-type="ref"} All standards recommend coordinated patient care and international collaboration in research.

In this study, we looked at the trends in cancer incidence and survival in children over a 15‐year period for Japan and England, by using population‐based cancer registry data and compared them during the same periods for each cancer type. One limitation of our study is the small number of records available in the Japanese dataset. Prefectural cancer registry data were only available for 6 prefectures, representing 14% of the total population,[10](#cas13457-bib-0010){ref-type="ref"} because other registries did not have such long‐term data with patients' vital status information. In 2013, a law for cancer registration was established in Japan and a nationwide cancer registration system started in 2016. Another limitation was the divergence between 5‐year survival and 10‐year survival (higher survival in 10‐year survival than 5‐year survival) in several cancers because we used the period approach to predict 10‐year survival in recent periods. To improve surveillance and comparability, we need to keep collecting data widely and precisely, and follow up patients' vital status in the long term.

In conclusion, the incidence rates of the majority of childhood cancers differed significantly between Japan and England. Some of these differences are explained by differences in national screening practices (infant neuroblastoma) and known differences in the genetics of Wilms tumor. Further research is needed to explore how much these variations in incidence are due to genetic susceptibility and/or environmental etiological factors. Regarding survival, an improvement was observed for most cancer types during the period 1993‐2008 in both countries. The increase was particularly notable for CML, following the introduction of effective, targeted treatment. Variations in survival may be due to differences in the tumor biology or in the treatment or in the health‐care service quality. The role for these factors will be further investigated through planned collaborative clinical and translational research between the 2 countries. Survival remained poor for 5 main cancer types, even in recent periods. This emphasizes the continuing need for new drug development while other opportunities for survival improvement should not be ignored, such as a better understanding of the potential impact of health‐care service organization and quality on survival, or through clinical studies to optimize the use of current treatments.
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